bezuclastinib – Talk Bio

Major Leadership Changes and Fundraising in Biotech: Metagenomi CEO Exit, Workforce Cuts; Cogent Biosciences Raises Over $475M

19 hours ago talkbio0Tagged bezuclastinib, Brian Thomas, CEO, Cogent Biosciences, Exit, Fund Raising, hemophilia A program, Irish (ethnic group), Jian, layoffs, Metagenomi, pipeline focus, Workforce

Metagenomi; CEO exit; Brian Thomas; Jian Irish; workforce cuts; biotech layoffs; Cogent Biosciences; fundraising; bezuclastinib; hemophilia A program; pipeline focus

Cogent Hits Unprecedented Efficacy in Rare Stomach Cancer, Clearing Path to FDA

3 days ago talkbio0Tagged bezuclastinib, Cogent Biosciences, Effectiveness, Frequency of Responses, Gastrointestinal Stromal Tumors, Infrequent, Malignant neoplasm of stomach, Progression-Free Survival, second-line treatment, Submission, United States Food and Drug Administration

Cogent Biosciences; bezuclastinib; unprecedented efficacy; rare stomach cancer; gastrointestinal stromal tumor (GIST); FDA submission; second-line treatment; objective response rate; progression-free survival

Cogent Biosciences Soars on Positive Phase 3 PEAK Results in Gastrointestinal Stromal Tumors (GIST)

3 days ago talkbio0Tagged bezuclastinib, Clinical Trials, Cogent Biosciences, Frequency of Responses, Gastrointestinal Stromal Tumors, NDA, Phase 3, Progression-Free Survival, Standard (qualifier), Stock Surge, Submission, sunitinib

Cogent Biosciences; bezuclastinib; sunitinib; GIST; Phase 3; progression-free survival; objective response rate; NDA submission; clinical trial; stock surge; standard of care